{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006213","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.472646+00:00","generated_at":"2026-05-16T03:12:42.132063+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Elite Pharmaceuticals to release Q3 FY2026 results Feb 17, host call Feb 18","bullets":["Q3 FY2026 financial results will be released on Tuesday, February 17, 2026.","Conference call on Wednesday, February 18, 2026 at 11:30 AM EST.","Dial-in: 1-800-346-7359 (domestic), 1-973-528-0008 (international), conference code 98840.","Stockholders may submit general questions by 5 PM EST Feb 16; financial questions by 7 PM EST Feb 17.","Questions can be emailed to dianne@elitepharma.com."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006213","json":"https://secwatch.observer/filing/0001493152-26-006213.json","markdown":"https://secwatch.observer/filing/0001493152-26-006213.md","text":"https://secwatch.observer/filing/0001493152-26-006213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226006213/0001493152-26-006213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226006213/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:12:42.132063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}